| 產(chǎn)品描述： | SNS-314 mesylate is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively |
| 靶點： |
Aurora A:9 nM (IC50);Aurora B:31 nM (IC50);Aurora C:6 nM (IC50);AuroraKinase |
| 體內(nèi)研究： |
In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off |
| 參考文獻： |
1. Oslob JD, et al. Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4. 2. Arbitrario JP, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. |
| 溶解性： |
DMSO : 150 mg/mL (284.61 mM; Need ultrasonic) |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.897 ml |
9.487 ml |
18.974 ml |
| 5 mM |
0.379 ml |
1.897 ml |
3.795 ml |
| 10 mM |
0.19 ml |
0.949 ml |
1.897 ml |
| 50 mM |
0.038 ml |
0.19 ml |
0.379 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京